Probiodrug Obtains Additional US Patent for the Inhibition of the Enzyme Glutaminyl Cyclase (QC) to Treat CNS Diseases
Probiodrug AG announced that Probiodrug has been granted US patent no. 7,732,162 covering additional subject matters for the company's QC inhibitors by the United States Patent Office. The patent comprises the use of QC inhibitors to treat mild cognitive impairment, neurodegeneration in Down syndrome, Familial British and Familial Danish dementia and the use of QC inhibitors to treat these diseases, as well as Alzheimer's disease, in combination with additional agents. These agents comprise, among others, beta amyloid antibodies, acetylcholinesterase (AChE) inhibitors, beta secretase inhibitors, and gamma secretase inhibitors.
„This is an important step to expand our patent estate around QC inhibition as a novel treatment paradigm in Alzheimer’s disease and other CNS diseases“, said Hans-Ulrich Demuth, CSO and co-founder of Probiodrug. „It extends our IP on QC inhibitor treatments to CNS diseases other than Alzheimer's and also to combination treatments, in which QC inhibitors are used alongside other compounds already marketed or under development.“
„Our patent estate now has grown to more than 35 patent families for QC inhibitors, including claims for composition of matter, formulations, and methods of treatment in various indications”, commented Matthias Hoffmann, VP Legal and Intellectual Property. „We have already been granted four patents in the US: one is the world's first patent covering broad methods to treat sporadic Alzheimer's disease using QC inhibitors, while the others cover QC inhibitors and the use of QC inhibitors in methods to treat CNS diseases such as Familial Alzheimer's diseases.“
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Généthon - Évry, France
Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
Biotec Pharmacon reports on neuroblastoma study
Merck Serono Appoints Steven Hildemann as Global Chief Medical Officer
Macrovipera_lebetina_obtusa
Scott Fabro to Join Evolva as Chief Commercial Officer
